New MRI contrast for brain tumors
Part of Brain & nervous system, Cancer, Ear, nose & throat clinical trials.
This trial uses a new type of MRI contrast dye (USPIO) to get clearer images of certain slow-growing brain tumors (vestibular schwannomas and low-grade gliomas). The goal is to see if this dye helps doctors better understand and treat these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 16 years old or older
- Have a vestibular schwannoma or low-grade glioma brain tumor
- Be able to lie still comfortably for up to 1 hour
- No previous radiation therapy to the brain or spine
- No allergy to iron or dextran (the contrast agent used in this MRI)
- Not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether two special MRI contrast medicines—gadolinium and ferumoxytol—can better diagnose problems in the brain or central nervous system. It may help doctors identify what’s causing symptoms or abnormal brain findings.
This trial tests a new imaging tracer that may help doctors see brain tumors (gliomas) more clearly before surgery. It could help guide treatment and is for people scheduled for surgery or biopsy.
This trial uses special MRI scans and a contrast agent to look at the immune environment of glioblastoma tumors. It may help doctors learn more about how the tumor responds to treatment.
This study uses special PET and MRI scans to map the activity and oxygen levels of brain tumors (gliomas). The results help doctors plan treatment that is more tailored to each patient.
This study is testing a new way of using MRI scans to see which parts of a brain tumour are low on oxygen. This could help doctors target radiation therapy more precisely and improve treatment for people with fast-growing brain tumours.
This study tests a new contrast agent (a dye injected before an MRI) to see how well it works for people having brain or spinal cord scans. It aims to improve image quality so doctors can see lesions more clearly, which may help with diagnosis and treatment planning.
Hear when a new Vestibular Schwannoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.